{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:35:29Z","timestamp":1792100129059,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T00:00:00Z","timestamp":1334534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T00:00:00Z","timestamp":1334534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1038\/leu.2012.104","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T06:38:19Z","timestamp":1334558299000},"page":"2172-2175","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":337,"title":["Standardized definitions of molecular response in chronic myeloid leukemia"],"prefix":"10.1038","volume":"26","author":[{"given":"N C P","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H E","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M C","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Saglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,4,16]]},"reference":[{"key":"BFleu2012104_CR1","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.462.462","volume":"114","author":"M Deininger","year":"2009","unstructured":"Deininger M, O\u2019Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114: 462 (abstract 1126).","journal-title":"Blood"},{"key":"BFleu2012104_CR2","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1056\/NEJMoa030513","volume":"349","author":"TP Hughes","year":"2003","unstructured":"Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423\u20131432.","journal-title":"N Engl J Med"},{"key":"BFleu2012104_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","volume":"108","author":"T Hughes","year":"2006","unstructured":"Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28\u201337.","journal-title":"Blood"},{"key":"BFleu2012104_CR4","doi-asserted-by":"publisher","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","volume":"27","author":"M Baccarani","year":"2009","unstructured":"Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009; 27: 6041\u20136051.","journal-title":"J Clin Oncol"},{"key":"BFleu2012104_CR5","doi-asserted-by":"publisher","first-page":"4933","DOI":"10.1182\/blood-2009-07-232595","volume":"114","author":"G Rosti","year":"2009","unstructured":"Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114: 4933\u20134938.","journal-title":"Blood"},{"key":"BFleu2012104_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2009.25.4896","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O\u2019Brien S, Jabbour E, Konopleva M, Ferrajoli A et al. Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase. J Clin Oncol 2010; 28: 392\u2013397.","journal-title":"J Clin Oncol"},{"key":"BFleu2012104_CR7","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2009.25.4920","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C et al. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol 2010; 28: 398\u2013404.","journal-title":"J Clin Oncol"},{"key":"BFleu2012104_CR8","doi-asserted-by":"crossref","unstructured":"Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M et al. A randomized phase II trial of dasatinib 100 mg vs imatinib 400\u2009mg in newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): the S0325 Intergroup trial. Blood 2010, 116 (abstract LBA-6).","DOI":"10.1182\/blood.V116.21.LBA-6.LBA-6"},{"key":"BFleu2012104_CR9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2012104_CR10","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2012104_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1182\/blood-2010-03-273979","volume":"116","author":"TP Hughes","year":"2010","unstructured":"Hughes TP, Hochhaus A, Saglio G, Kim DW, Jootar S, le Coutre PD et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). Blood 2010; 116: 94\u201395, (abstract 0207).","journal-title":"Blood"},{"key":"BFleu2012104_CR12","first-page":"459","volume":"95","author":"A Hochhaus","year":"2010","unstructured":"Hochhaus A, Lobo C, Pasquini R, Clark R, Kim DW, Issaragrisil S et al. Continued superiority of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond 1 year. Haematologica 2010; 95: 459 (abstract 1113).","journal-title":"Haematologica"},{"key":"BFleu2012104_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","volume":"12","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12: 841\u2013851.","journal-title":"Lancet Oncol"},{"key":"BFleu2012104_CR14","doi-asserted-by":"crossref","unstructured":"Gugliotta G, Castagnetti F, Breccia M, Levato L, Capucci A, Tiribelli M et al. Early CP CML, Nilotinib 400\u2009mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood 2011; 116, abstract 2756.","DOI":"10.1182\/blood.V118.21.2756.2756"},{"key":"BFleu2012104_CR15","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123\u20131129.","journal-title":"Blood"},{"key":"BFleu2012104_CR16","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-10-2922","volume":"17","author":"HM Kantarjian","year":"2011","unstructured":"Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE . Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. Clin Cancer Res 2011; 17: 1674\u20131683.","journal-title":"Clin Cancer Res"},{"key":"BFleu2012104_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V99.1.319","volume":"99","author":"SM Graham","year":"2002","unstructured":"Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319\u2013325.","journal-title":"Blood"},{"key":"BFleu2012104_CR18","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","volume":"104","author":"J Cortes","year":"2004","unstructured":"Cortes J, O\u2019Brien S, Kantarjian H . Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204\u20132205.","journal-title":"Blood"},{"key":"BFleu2012104_CR19","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2012104_CR20","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/leu.2010.185","volume":"10","author":"DM Ross","year":"2010","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 2010; 10: 1719\u20131724.","journal-title":"Leukemia"},{"key":"BFleu2012104_CR21","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V86.5.2041.bloodjournal8652041","volume":"86","author":"HJ Kolb","year":"1995","unstructured":"Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041\u20132050.","journal-title":"Blood"},{"key":"BFleu2012104_CR22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/blood.V95.1.62","volume":"95","author":"A Hochhaus","year":"2000","unstructured":"Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000; 95: 62\u201366.","journal-title":"Blood"},{"key":"BFleu2012104_CR23","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","volume":"98","author":"F Bonifazi","year":"2001","unstructured":"Bonifazi F, de Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074\u20133081.","journal-title":"Blood"},{"key":"BFleu2012104_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/cncr.11223","volume":"97","author":"HM Kantarjian","year":"2003","unstructured":"Kantarjian HM, O\u2019Brien S, Cortes JE, Shan J, Giles FJ, Rios MB et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97: 1033\u20131041.","journal-title":"Cancer"},{"key":"BFleu2012104_CR25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","volume":"28","author":"A Burchert","year":"2010","unstructured":"Burchert A, M\u00fcller MC, Kostrewa P, Erben P, Bostel T, Liebler S et al. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 2010; 28: 1429\u20131435.","journal-title":"J Clin Oncol"},{"key":"BFleu2012104_CR26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1182\/blood.V116.21.227.227","volume":"116","author":"B Zhang","year":"2010","unstructured":"Zhang B, Irvine D, Ho YW, Buonamici S, Manley P, Holyoake TL et al. Inhibition of chronic myeloid leukemia stem cells by the combination of the hedgehog pathway inhibitor LDE225 with nilotinib. Blood 2010; 116: 227 (abstract 514).","journal-title":"Blood"},{"key":"BFleu2012104_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.leukres.2011.12.002","volume":"36","author":"RR Nair","year":"2012","unstructured":"Nair RR, Tolentino JH, Argilagos RF, Zhang L, Pinilla-Ibarz J, Hazlehurst LA . Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML. Leuk Res 2012; 36: 756\u2013763.","journal-title":"Leuk Res"},{"key":"BFleu2012104_CR28","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ccr.2011.11.004","volume":"20","author":"LM Packer","year":"2011","unstructured":"Packer LM, Rana S, Hayward R, O\u2019Hare T, Eide CA, Rebocho A et al. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 2011; 20: 715\u2013727.","journal-title":"Cancer Cell"},{"key":"BFleu2012104_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/blood-2010-08-303495","volume":"119","author":"A Kumari","year":"2012","unstructured":"Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A . Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 2012; 119: 530\u2013539.","journal-title":"Blood"},{"key":"BFleu2012104_CR30","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.V87.6.2588.bloodjournal8762588","volume":"87","author":"JG Zhang","year":"1996","unstructured":"Zhang JG, Lin F, Chase A, Goldman JM, Cross NC . Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. Blood 1996; 87: 2588\u20132593.","journal-title":"Blood"},{"key":"BFleu2012104_CR31","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/blood-2009-11-255109","volume":"116","author":"M Sobrinho-Simoes","year":"2010","unstructured":"Sobrinho-Simoes M, Wilczek V, Score J, Cross NC, Apperley JF, Melo JV . In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib. Blood 2010; 116: 1329\u20131335.","journal-title":"Blood"},{"key":"BFleu2012104_CR32","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nrclinonc.2011.17","volume":"8","author":"M Deininger","year":"2011","unstructured":"Deininger M . Hematology: curing CML with imatinib\u2014a dream come true? Nat Rev Clin Oncol 2011; 8: 127\u2013128.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu2012104_CR33","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1182\/blood.V118.21.278.278","volume":"118","author":"TP Hughes","year":"2011","unstructured":"Hughes TP, Lipton JH, Leber B, Spector N, Cervantes F, Pasquini R et al. Complete molecular response (CMR) rate with nilotinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) without CMR after \u2a7e2 years on imatinib: preliminary results from the randomized ENESTcmr trial of nilotinib 400\u2009mg twice daily (BID) vs imatinib. Blood 2011; 118: 278 (abstract 606).","journal-title":"Blood"},{"key":"BFleu2012104_CR34","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1182\/blood-2008-04-150680","volume":"112","author":"S Branford","year":"2008","unstructured":"Branford S, Fletcher L, Cross NC, M\u00fcller MC, Hochhaus A, Kim DW et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008; 112: 3330\u20133338.","journal-title":"Blood"},{"key":"BFleu2012104_CR35","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1038\/leu.2009.168","volume":"23","author":"MC M\u00fcller","year":"2009","unstructured":"M\u00fcller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia 2009; 23: 1957\u20131963.","journal-title":"Leukemia"},{"key":"BFleu2012104_CR36","doi-asserted-by":"publisher","first-page":"e111","DOI":"10.1182\/blood-2010-06-291641","volume":"116","author":"HE White","year":"2010","unstructured":"White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Wang YL et al. Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood 2010; 116: e111\u2013e117.","journal-title":"Blood"},{"key":"BFleu2012104_CR37","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.leu.2403136","volume":"17","author":"E Beillard","year":"2003","unstructured":"Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)\u2014a Europe against cancer program. Leukemia 2003; 17: 2474\u20132486.","journal-title":"Leukemia"},{"key":"BFleu2012104_CR38","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1182\/blood.V118.21.1186.1186","volume":"118","author":"F Giles","year":"2011","unstructured":"Giles F, Rosti G, Ossenkoppele GJ, Tulliez M, Stentoft J, Giagounidis A et al. A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission. Blood 2011; 118: 1186\u20131187, (abstract 2759).","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2012104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012104","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2012104.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:14:26Z","timestamp":1648739666000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2012104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,16]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["BFleu2012104"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.104","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,16]]},"assertion":[{"value":"5 March 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}